http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MA-31748-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33eaca90fe66a7c52bd9c7c4cf353a58
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-731
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-14
filingDate 2010-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93105a4f5ca246e85c3f3338721c4e4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ee74270417fbcb17ea266bb2f5312ba
publicationDate 2010-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MA-31748-B1
titleOfInvention An antiviral composition containing sulfated polysaccharide
abstract The present invention relates to the use of iota- and / or kappa carrageenan for the manufacture of an antiviral pharmaceutical composition for the prevention or treatment of a pathological condition or disease caused by or associated with infection with a selected respiratory virus. from the group consisting of orthomyxoviruses, paramyxoviruses, adenoviruses and coronaviruses. The present invention also relates to the use of fucoidan, especially high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prevention or treatment of a pathological condition or disease caused by or associated with infection with an respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus
priorityDate 2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426185960
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11966249

Total number of triples: 30.